JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

Home・Akciju saraksts・Pulmatrix Inc

Pulmatrix Inc

Slēgts

2.42 -4.35

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.42

Max

2.5300000000000002

Galvenie mērījumi
By Trading Economics
Ienākumi	672K -877K
EPS	-0.24
Peļņas marža	-60,266.667
Darbinieki	2
EBITDA	671K -877K

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-8.4M 9.5M
Iepriekšējā atvēršanas cena	6.77
Iepriekšējā slēgšanas cena	2.42

Pulmatrix Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 5. febr. 23:57 UTC

Peļņas

Naver Has Record Year Despite Weaker Final Quarter

2026. g. 5. febr. 23:45 UTC

Karstas akcijas

Stocks to Watch: Amazon, Coty, Gen Digital, Roblox

2026. g. 5. febr. 22:26 UTC

Peļņas

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9% -- Update

2026. g. 5. febr. 22:00 UTC

Peļņas

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9%

2026. g. 5. febr. 23:47 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 5. febr. 23:47 UTC

Tirgus saruna

Nikkei May Fall After U.S. Tech Stock Drops -- Market Talk

2026. g. 5. febr. 23:43 UTC

Tirgus saruna

Gold Falls on Spillover Impact From Cryptocurrencies' Selloff -- Market Talk

2026. g. 5. febr. 23:37 UTC

Tirgus saruna

Glencore Shares Look Cheap After Failed Takeover Talks -- Market Talk

2026. g. 5. febr. 23:20 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 5th Update

2026. g. 5. febr. 23:11 UTC

Tirgus saruna

Amazon CEO Confident in Return on $200B Investment -- Market Talk

2026. g. 5. febr. 23:09 UTC

Peļņas

Naver 2025 Net KRW1.820T Vs. Net KRW1.932T >035420.SE

2026. g. 5. febr. 23:08 UTC

Peļņas

Naver 2025 Oper Pft KRW2.208T Vs. Pft KRW1.979T >035420.SE

2026. g. 5. febr. 23:07 UTC

Peļņas

Naver 2025 Rev KRW12.035T Vs. KRW10.738T >035420.SE

2026. g. 5. febr. 23:03 UTC

Tirgus saruna

Peļņas

REA's Update Looks Negative Despite A$200M Buyback -- Market Talk

2026. g. 5. febr. 23:03 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Bitcoin Booster's $12 Billion Loss Headlines Crypto's Worst Day Since 2022 Crash -- WSJ

2026. g. 5. febr. 23:00 UTC

Peļņas

Naver 4Q Net Profit Missed FactSet-Compiled Consensus

2026. g. 5. febr. 23:00 UTC

Peļņas

Naver 4Q Net KRW164.60B Vs. Net KRW514.00B >035420.SE

2026. g. 5. febr. 22:59 UTC

Peļņas

Naver 4Q Oper Pft KRW610.60B Vs. Pft KRW542.00B >035420.SE

2026. g. 5. febr. 22:59 UTC

Peļņas

Naver 4Q Rev KRW3.195T Vs. KRW2.886T >035420.SE

2026. g. 5. febr. 22:52 UTC

Peļņas

Alphabet Stock Is Taking a Hit After Strong Earnings. Don't Panic. -- Barrons.com

2026. g. 5. febr. 22:45 UTC

Peļņas

Amazon Stock Falls Sharply on Earnings. Spending Continues to Soar. -- Barrons.com

2026. g. 5. febr. 22:37 UTC

Tirgus saruna

Woolworths's Profit Margin Likely Faces 2Q Squeeze -- Market Talk

2026. g. 5. febr. 22:11 UTC

Peļņas

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9% -- Update

2026. g. 5. febr. 22:03 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 4th Update

2026. g. 5. febr. 22:01 UTC

Peļņas

Reddit Stock Jumps on Earnings. CFO Cites Modest AI Spending. -- Barrons.com

2026. g. 5. febr. 21:59 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

What's Next For Rio Tinto, Glencore After Deal Talks Fail? -- Market Talk

2026. g. 5. febr. 21:51 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Saylor's Strategy Posts $12 Billion Quarterly Loss on Bitcoin Selloff -- WSJ

2026. g. 5. febr. 21:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Basic Materials Roundup: Market Talk

2026. g. 5. febr. 21:49 UTC

Peļņas

Why Google's Bad News Was Good News for Broadcom and Nvidia -- Barrons.com

2026. g. 5. febr. 21:45 UTC

Peļņas

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9%

Salīdzinājums

Cenas izmaiņa

Pulmatrix Inc Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 0 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Pulmatrix Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Pulmatrix Inc

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.